Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of apitegromab (SRK-015) in later-onset spinal muscular atrophy
2018-004383-65Phase 2Completed
- Sponsor
- Scholar Rock
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of apitegromab in spinal muscular atrophy (SMA) and Spinal muscular atrophy type 3 (SMA3) (3 cohorts), sponsored by Scholar Rock. Primary endpoint: Primary endpoint – Cohort 1 (ambulatory type 3 SMA). Started Apr 2019; status: completed.
02
Drugs
apitegromab
03
Conditions
spinal muscular atrophy (SMA)Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on 2018-004383-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004383-65.